The global specimen collection cards market size is likely to be valued at US$512.2 million in 2026 and is expected to reach US$720.7 million by 2033, growing at a CAGR of 5.0% during the forecast period from 2026 to 2033, driven by increasing adoption of dried sample collection technologies in newborn screening, infectious disease diagnostics, molecular testing, and decentralized healthcare programs.

Specimen collection cards enable safe, cost-effective collection, storage, and transport of biological samples while preserving sample integrity for PCR, mass spectrometry, and other advanced analyses. Growing adoption in newborn screening, remote sample collection, and genomic testing continues to drive market demand.

Driver - Growth in Infectious Diseases Testing and Point-of-Care Diagnostics

Healthcare systems worldwide are strengthening disease surveillance programs to detect infections earlier and improve public health responses. Specimen collection cards offer a practical solution for collecting, storing, and transporting biological samples without requiring extensive cold-chain infrastructure. Their ability to preserve sample integrity over long periods makes them valuable for large-scale screening initiatives and outbreak monitoring.

Growing utilization of molecular diagnostic techniques, including PCR-based testing, has increased demand for reliable dried sample collection methods that support accurate laboratory analysis across diverse healthcare environments. The expansion of point-of-care diagnostics is accelerating the adoption of specimen collection cards across clinical and decentralized healthcare settings.

Healthcare providers increasingly seek convenient sample collection solutions that reduce logistical complexity while maintaining testing accuracy. Specimen collection cards enable remote sampling, home-based collection, and access to diagnostics in underserved regions where laboratory infrastructure may be limited. Their compatibility with advanced diagnostic platforms supports broader implementation of personalized healthcare and disease monitoring programs.

Restraint - Sample Quality and Interpretation Variability

Differences in collection techniques, drying conditions, storage environments, and transportation practices can affect sample consistency and analytical performance. Variations in blood volume, specimen distribution, and environmental exposure may influence test results and create challenges for laboratories seeking standardized outcomes. Such inconsistencies can impact diagnostic accuracy, particularly when highly sensitive molecular or biochemical analyses are performed.

Interpretation variability also presents limitations for widespread implementation of specimen collection card technologies. Differences in laboratory protocols, extraction methods, and analytical platforms may contribute to inconsistent findings across testing facilities. Regulatory agencies and healthcare organizations increasingly emphasize quality assurance, standardization, and reproducibility, requiring manufacturers to demonstrate robust performance under diverse conditions.

Opportunity - Technological Convergence with Digital and Multi-Omics Applications

Advances in genomics, proteomics, metabolomics, and transcriptomics are increasing the demand for reliable sample preservation solutions capable of supporting complex analyses. Specimen collection cards provide a convenient platform for collecting biological samples that can be integrated into next-generation diagnostic workflows.

Their compatibility with molecular testing technologies enables efficient sample management while supporting large-scale research initiatives. As precision medicine gains momentum, healthcare organizations and researchers increasingly require scalable collection methods that facilitate comprehensive biological profiling and data-driven clinical decision-making across diverse populations.

The growing adoption of digital health platforms enhances the market potential for specimen collection cards. Integration with electronic health records, remote monitoring systems, and digital diagnostic ecosystems supports streamlined sample tracking and improved patient engagement. Decentralized clinical trials increasingly utilize remote specimen collection technologies to improve participation and reduce operational burdens.

Product Type Insights

Whatman 903 is expected to lead, accounting for 40% of the revenue share in 2026, due to its long-standing use in dried blood spot collection and its widespread acceptance across newborn screening, clinical diagnostics, and public health testing programs. The product continues to serve as a standard collection medium in several national screening initiatives where accuracy and reproducibility are critical. A notable example includes the use of Whatman 903 cards in newborn screening programs, where dried blood spot samples are routinely collected and transported for metabolic and genetic disease testing.

FTA is likely to represent the fastest-growing segment, supported by its advanced capabilities in preserving nucleic acids for downstream molecular analysis. The segment is benefiting from increasing demand for genetic testing, pathogen detection, forensic investigations, and precision medicine applications. For instance, the use of FTA cards in forensic DNA profiling allows biological samples to be collected, preserved, and analyzed efficiently while maintaining sample integrity.

Specimen Type Insights

The blood segment is projected to lead the market, capturing around 70% of the revenue share in 2026, supported by the extensive use of dried blood spot collection methods across newborn screening, infectious disease testing, therapeutic drug monitoring, and epidemiological studies. Dried blood spot technology offers simplified transportation and storage compared with conventional liquid blood samples. For example, newborn screening programs where blood samples collected on specimen cards are routinely analyzed to identify inherited metabolic and genetic disorders shortly after birth.

Saliva is likely to be the fastest-growing specimen type due to the increasing demand for convenient and non-invasive sample collection methods. Saliva-based collection eliminates the need for needles and specialized collection personnel, making it highly attractive for home testing, population screening, and consumer health applications. For instance, direct-to-consumer genetic testing, where saliva specimens are collected and analyzed to provide ancestry, wellness, and genetic trait information.

Application Insights

Newborn screening is expected to account for 40% of revenue in 2026, due to well-established public health programs designed to identify serious congenital and metabolic disorders during the earliest stages of life. Specimen collection cards play a critical role in enabling efficient dried blood spot collection shortly after birth, allowing laboratories to perform comprehensive screening for multiple conditions from a single sample. For example, national newborn screening programs that utilize dried blood spot cards to detect disorders such as phenylketonuria and congenital hypothyroidism.

Infectious diseases testing is likely to represent the fastest-growing segment, supported by increasing emphasis on disease surveillance, outbreak monitoring, and decentralized diagnostic services. Healthcare organizations are investing heavily in technologies that enable efficient sample collection and transportation while maintaining analytical reliability. A notable example includes the use of dried blood spot cards for HIV surveillance and monitoring programs, where samples can be collected remotely and transported efficiently for laboratory analysis.

North America Specimen Collection Cards Market Trends

North America is anticipated to be the leading region, accounting for a market share of 40% in 2026, supported by the strong presence of newborn screening programs, advanced molecular diagnostics infrastructure, and widespread adoption of decentralized testing models. Investments in precision medicine and population health initiatives support market expansion. For instance, CENTOGENE N.V., which continues to expand dried blood spot-based genetic testing services for rare disease diagnostics, highlights the growing role of specimen collection cards in decentralized genomic testing.

U.S. Specimen Collection Cards Market Trends

The U.S. is expected to dominate, accounting for approximately 80% of the regional market share in 2026. Nationwide newborn screening programs continue to support extensive utilization of dried blood spot cards. Increasing adoption of molecular diagnostics and genomic testing is creating additional demand for advanced specimen collection solutions. Healthcare organizations are expanding remote and home-based testing services to improve patient accessibility. Growth in precision medicine programs is increasing specimen collection requirements.

Canada Specimen Collection Cards Market Trends

Canada is expected to be a significant market for specimen collection cards, accounting for approximately 20% of the regional market share in 2026. Growth is driven by expanding public health initiatives and laboratory testing programs. Provincial newborn screening programs continue to generate strong demand for dried blood spot technologies, while increasing emphasis on improving healthcare access in rural and remote areas is accelerating the adoption of specimen collection cards for reliable sample collection and transport. In addition, growing genomic and biomarker research is further supporting the demand for stable sample preservation solutions.

Europe Specimen Collection Cards Market Trends

Europe is likely to be a significant market for specimen collection cards, due to increasing emphasis on early disease detection, genetic screening, and advanced laboratory diagnostics. The region benefits from strong healthcare infrastructure and growing adoption of precision medicine initiatives. For instance, QIAGEN, which supports molecular testing workflows widely used across European healthcare and research institutions, contributing to the advancement of specimen-based diagnostic solutions.

U.K. Specimen Collection Cards Market Trends

The U.K. is likely to be a significant market, accounting for 30% of the Europe market share in 2026. National screening programs remain a major contributor to market demand. The expansion of genomic medicine initiatives is creating new opportunities for dried sample collection technologies. Healthcare organizations are investing in innovative testing models that support patient convenience and broader diagnostic access. Academic institutions are conducting large-scale research projects requiring efficient specimen preservation.

Germany Specimen Collection Cards Market Trends

Germany is anticipated to be the leading country in Europe, accounting for around 27% of the regional market share in 2026, due to strong diagnostic laboratory infrastructure supporting the extensive use of dried specimen technologies. Newborn screening programs continue to drive consistent demand for blood collection cards. German healthcare institutions are increasingly investing in molecular diagnostics and genomic medicine initiatives. Research organizations are expanding studies involving biomarker discovery and precision medicine applications.

Asia Pacific Specimen Collection Cards Market Trends

The Asia Pacific region is likely to be the fastest-growing region, driven by expanding healthcare infrastructure, rising diagnostic testing volumes, and increasing government investments in disease screening initiatives. The region is also benefiting from increasing utilization of molecular diagnostics, genetic testing, and decentralized healthcare models. A notable example is Ahlstrom, whose specimen collection card materials are used in diagnostic and screening applications to support reliable sample preservation for healthcare and research organizations.

China Specimen Collection Cards Market Trends

China is projected to dominate the regional market, accounting for around 30% of the Asia Pacific market share in 2026. Growth is driven by the rapid expansion of healthcare infrastructure, increasing access to diagnostic services, and government-supported disease screening programs that are accelerating the adoption of dried specimen collection technologies. Rising use of molecular diagnostics and genomic testing across hospitals and research institutions, along with the growing implementation of advanced testing workflows requiring reliable sample preservation, continues to support market growth.

India Specimen Collection Cards Market Trends

India is expected to account for approximately 27% of the regional market share in 2026, due to increasing healthcare accessibility and growing awareness of preventive diagnostics. Expansion of newborn screening and infectious disease testing programs is supporting market demand. Healthcare providers are adopting cost-effective sample collection technologies suitable for geographically diverse populations. The growth of molecular diagnostics and genomic research is creating additional opportunities for specimen collection card utilization.

The global specimen collection cards market exhibits a moderately fragmented structure, driven by the presence of established diagnostics companies, specialized sample collection technology providers, and manufacturers of laboratory consumables. Market growth is supported by increasing demand for newborn screening, infectious disease surveillance, molecular diagnostics, and decentralized testing solutions.

With key leaders, including QIAGEN, PerkinElmer Inc., Danaher Corporation, Ahlstrom, and CENTOGENE N.V., the market continues to evolve through innovation and strategic expansion. These players compete through product development, improvements in specimen preservation technologies, expansion of molecular testing capabilities, strategic collaborations with healthcare and research organizations, and investments in decentralized diagnostic solutions.

Key Industry Developments:

• In October 2025, Ahlstrom acquired EBF, a leading manufacturer of newborn screening devices and specimen collection cards, strengthening its presence in the life sciences and diagnostics market while expanding its capabilities in specimen collection solutions for blood and urine testing applications.